Table 1 Clinical, biochemical, and therapeutic characteristics of the study patients
|  | All (n = 194) | Non-CH group (n = 149) | CH group (n = 45) | P value |
|---|---|---|---|---|
Age, years | 55.3 ± 11.7 | 55.9 ± 11.7 | 53.3 ± 11.7 | 0.186 |
Female (%) | 44.3 | 46.3 | 37.8 | 0.313 |
Dialysis vintage, years | 13.0 ± 6.3 | 13.6 ± 6.4 | 11.1 ± 5.7 | 0.020 |
Underlying diseases (%) | ||||
 CGN | 54.1 | 55.0 | 51.1 | 0.747 |
 DMn | 8.8 | 7.4 | 13.3 | |
 Nephrosclerosis | 6.7 | 6.7 | 6.7 | |
 PCK | 8.8 | 8.1 | 11.1 | |
 Others | 3.6 | 3.4 | 44.4 | |
 Unknown | 18.0 | 19.5 | 13.3 | |
WBC (/μL) | 4916.6 ± 1283.2 | 4805.4 ± 1253.4 | 5284.9 ± 1325.9 | 0.027 |
Hb (g/dL) | 10.6 ± 1.4 | 10.5 ± 1.4 | 10.8 ± 1.5 | 0.265 |
Plt (× 104/μL) | 18. 2 ± 5.3 | 18.0 ± 5.1 | 18.8 ± 5.8 | 0.360 |
TP (g/dL) | 6.3 ± 0.5 | 6.3 ± 0.5 | 6.3 ± 0.4 | 0.385 |
Alb (g/dL) | 3.7 ± 0.3 | 3.7 ± 0.3 | 3.7 ± 0.3 | 0.183 |
SUN (mg/dL) | 64.2 ± 16.5 | 64.9 ± 16.9 | 61.8 ± 14.9 | 0.286 |
Cr (mg/dL) | 12.5 ± 3.0 | 12.5 ± 3.0 | 12.6 ± 2.9 | 0.841 |
ALP(U/L) | 398.5 ± 284.3 | 386.1 ± 230.7 | 483.7 ± 413.5 | 0.419 |
corrected Ca (mg/dL) | 10.1 ± 0.9 | 10.2 ± 0.8 | 9.7 ± 1.0 | < 0.001 |
P (mg/dL) | 6.3 ± 1.3 | 6.3 ± 1.3 | 6.0 ± 1.5 | 0.168 |
Intact PTH (pg/mL) | 740.1 ± 408.1 | 764.6 ± 373.9 | 662.4 ± 498.5 | 0.210 |
CaCO3 (%) | 47.4 | 45.0 | 55.6 | 0.213 |
(Dose g/day) | 2.7 ± 1.9 | 2.6 ± 1.9 | 3.1 ± 1.7 | 0.252 |
Non-Ca containing P binders (%) | 79.4 | 83.9 | 86.7 | 0.139 |
Oral VDRA (%) | 4.1 | 4.0 | 4.4 | 0.902 |
Intravenous VDRA (%) | 59.8 | 57.7 | 66.7 | 0.283 |
CH (%) | 23.2 | 0 | 100 | – |